Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Intravesical therapy - BCG and beyond

Grossman, H. Barton ; Lamm, Donald ; Sjodahl, Gottfrid LU ; O'donnell, Michael ; Hahn, Noah and Kamat, Ashish (2019) In Bladder Cancer 5(1). p.73-80
Abstract

Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette-Gúerin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.

Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Bcg, Bladder cancer, Immunotherapy, Intravesical chemotherapy, Molecular profiling
in
Bladder Cancer
volume
5
issue
1
pages
8 pages
publisher
IOS Press
external identifiers
  • scopus:85061048329
ISSN
2352-3727
DOI
10.3233/BLC-180198
language
English
LU publication?
yes
id
1b82633d-9241-46f1-a248-46eca88fe1c9
date added to LUP
2019-02-12 13:19:16
date last changed
2022-05-03 18:09:28
@article{1b82633d-9241-46f1-a248-46eca88fe1c9,
  abstract     = {{<p>Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette-Gúerin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.</p>}},
  author       = {{Grossman, H. Barton and Lamm, Donald and Sjodahl, Gottfrid and O'donnell, Michael and Hahn, Noah and Kamat, Ashish}},
  issn         = {{2352-3727}},
  keywords     = {{Bcg; Bladder cancer; Immunotherapy; Intravesical chemotherapy; Molecular profiling}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{73--80}},
  publisher    = {{IOS Press}},
  series       = {{Bladder Cancer}},
  title        = {{Intravesical therapy - BCG and beyond}},
  url          = {{http://dx.doi.org/10.3233/BLC-180198}},
  doi          = {{10.3233/BLC-180198}},
  volume       = {{5}},
  year         = {{2019}},
}